Aoa Dx is developing the next frontier in early-stage cancer detection for women through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, Glycolocate™, is paving the way for life-saving early cancer detection. In a first of its kind, Aoa Dx is developing Akrivis GD™, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. Aoa Dx was co-founded by three experts and passionate advocates of women’s health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization.
Aoa Dx, a Y Combinator and VC backed company, raised an oversubscribed seed round to accelerate development and clinical studies.
